Cargando…
BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells
Osteosarcoma (OS) survival rates have plateaued in part due to a lack of new therapeutic options. Here we demonstrate that bromodomain inhibitors (BETi), JQ1, I-BET151, I-BET762, exert potent anti-tumour activity against primary and established OS cell lines, mediated by inhibition of BRD4. Striking...
Autores principales: | Baker, Emma K, Taylor, Scott, Gupte, Ankita, Sharp, Phillip P, Walia, Mannu, Walsh, Nicole C, Zannettino, Andrew CW, Chalk, Alistair M, Burns, Christopher J, Walkley, Carl R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421868/ https://www.ncbi.nlm.nih.gov/pubmed/25944566 http://dx.doi.org/10.1038/srep10120 |
Ejemplares similares
-
Activation of PTHrP-cAMP-CREB1 signaling following p53 loss is essential for osteosarcoma initiation and maintenance
por: Walia, Mannu K, et al.
Publicado: (2016) -
IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα
por: Shekhar, Tanmay M., et al.
Publicado: (2016) -
EEF2K silencing inhibits tumour progression through repressing SPP1 and synergises with BET inhibitors in melanoma
por: Deng, Guangtong, et al.
Publicado: (2022) -
PTHrP, its receptor, and protein kinase A activation in osteosarcoma
por: Walkley, Carl R, et al.
Publicado: (2014) -
Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
por: Bolin, Sara, et al.
Publicado: (2018)